UPCC 02921: A Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients with Advanced Cancer Including Immunotherapy Refractory Expansion Cohorts With and Without Pembrolizumab
Enrolling By Invitation
99 years and younger
All
Phase
N/A
1 Location
Brief description of study
This Phase 1, first-in-human, open-label, multicenter study follows a 3+3 ascending dose escalation design to determine the MTD/RP2D and to characterize the safety, tolerability, PK, and antitumor effects of LNS8801 alone and in combination with pembrolizumab. The study will include a dose escalation and a dose expansion phase. **PENNSYLVANIA HOSPITAL IS ONLY PARTICIPATING IN THE DOSE EXPANSION COHORT.**
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Updated on
14 Aug 2024.
Study ID: 848374
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
